Revelation Biosciences, Inc. REVB
Revelation Biosciences, Inc. (Nasdaq: REVB) is a cardio-renal-metabolic drug developer. Its lead program, Gemini (PHAD formulation), GEM-AKI, is in Phase 1 for Acute kidney injury.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| GEM-AKI | Acute kidney injury | small molecule | Phase 1 |
| GEM-CKD | Chronic kidney disease | small molecule | Phase 1 |
Recent results and decisions
- Aug 17, 2026n/a Revelation Biosciences granted performance-based restricted stock awards to CEO James Rolke (208,076 shares) and CFO Chester Zygmont (208,073 shares) on August 17, 2026.
Mr. Rolke received a Restricted Stock Award covering 208,076 shares of the Company's common stock, and Mr. Zygmont received a Restricted Stock Award covering 208,073 shares of the Company's common stock.
Filing - Jan 21, 2026n/a Agreement with FDA that a single Phase 2/3 adaptive study (about 300 patients, composite of death and/or dialysis) could support an NDA.
positive data from a single well-controlled Phase 2/3 adaptive design clinical study, comprising approximately 300 patients, would be sufficient for submission of a new drug application (NDA)
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.